Essais liés17clinical trials
VilleMadridlocalisation
PaysSpainlocalisation
SourcelocaleCSV/MySQL

Informations

centre

Synchronisé depuis ClinicalTrials.gov — NCT07064473

Ouvrir le site du centre

Essais cliniques associés

17
MoléculeIndication / populationPhaseNCTTitreStatut
Prasinezumab Parkinson Phase 2 NCT04777331 PADOVA — A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease ACTIVE_NOT_RECRUITING
RO7046015 Parkinson Phase 2 NCT03100149 PASADENA — A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease ACTIVE_NOT_RECRUITING
Inavolisib Cancer Phase 3 NCT06790693 INAVO123 — A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer RECRUITING
Nerandomilast Myopathies Phase 3 NCT07789015 VERANDA™-IIM — A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies NOT_YET_RECRUITING
Ocrelizumab SEP Phase 3 NCT05123703 Operetta 2 — A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS) ACTIVE_NOT_RECRUITING
Vicadrostat Hypertension Phase 3 NCT07064473 EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease RECRUITING
Monoclonal antibody anti-CGRP Migraine À vérifier NCT06459648 PREDI-CGRP — Study for Prevent Chronification Migraine Through Prediction of Response to Treatment With Anti-CGRP Antibodies RECRUITING
Trontinemab Alzheimer Phase 3 NCT07169578 TRONTIER 1 — A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease RECRUITING
Prasinezumab Parkinson Phase 3 NCT07174310 PARAISO — A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease RECRUITING
Ocrelizumab SEP Phase 3 NCT05269004 OLERO — A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis ACTIVE_NOT_RECRUITING
Atogepant 60 mg Migraine À vérifier NCT07699549 GEMA PROJECT — Long-term Atogepant in Real-world Practice COMPLETED
Ocrelizumab Test Formulation SEP Phase 2 NCT07074886 PORTAMENTO — A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS) ACTIVE_NOT_RECRUITING
PREDI-CRISIS — Migraine Attack Pain Phase Prediction Study Migraine À vérifier NCT06459635 PREDI-CRISIS — Migraine Attack Pain Phase Prediction Study RECRUITING
Ponesimod SEP Phase 3 NCT03232073 Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple Sclerosis COMPLETED
Fenebrutinib SEP Phase 2 NCT07161258 FENerations1 — A Pharmacokinetics (PK), Pharmacodynamics (PD), Safety and Tolerability Study of Fenebrutinib in Children and Adolescents With Relapsing Multiple Sclerosis (RMS) RECRUITING
Fenebrutinib SEP Phase 3 NCT04586010 FENhance — A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS) ACTIVE_NOT_RECRUITING
CVN424 75 mg Parkinson Phase 3 NCT06553027 To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications ACTIVE_NOT_RECRUITING